AIxCrypto Holdings, Inc. (AIXC) Stock Score, Valuation & Financial Research

AIxCrypto Holdings, Inc. is in the Technology sector and Software - Infrastructure industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AIXC

AIxCrypto Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.37. These figures are a research snapshot, not a buy or sell recommendation.

What AIxCrypto Holdings, Inc. does

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

AIxCrypto Holdings, Inc. is a digital infrastructure company focused on the development of Real World Asset (RWA) tokenization, AI agents, and Embodied AI (EAI) blockchain ecosystems. The company generates value through the strategic development of these platforms to bridge Web2 and Web3 technologies, following a 2025 corporate pivot and rebranding.

Products and services

  • Development of infrastructure for Real World Asset (RWA) tokenization, AI agents, and Embodied AI (EAI) blockchain ecosystems for intelligent devices.

Business strengths to evaluate

  • Strategic repositioning and capital formation following a $41.0 million private placement Source

Business risks and research considerations

  • Operational risks associated with the transformation from a biopharmaceutical company to a digital infrastructure business Source

Sources: Company research source · Strategic repositioning and capital formation following a $41.0 million private placement

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AIXC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.37
Market capitalization:
27.72M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -22.9M
Free cash flow:
USD -23.54M
Cash:
USD 577.33K
Total debt:
USD 39.56K
EPS:
USD -9.44

What stands out

  • Free cash flow is USD -23.54M, negative for the stored period.
  • The balance sheet shows USD 577.33K of cash versus USD 39.56K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 537.77K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AIXC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AIXC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AIXC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AIXC to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of AIXC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-16.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AIXC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.